Cor Vasa 2012, 54(5-6):302-304-305

Kardiovaskulární kontinuum. Rozhodují komorbidity o volbě terapie?

Prof. MUDr. Jindřich ©pinar, CSc., FESC
I. interní kardiologická klinika, Lékařská fakulta Masarykovy univerzity a Fakultní nemocnice Brno, Brno

Published: May 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
©pinar J. Kardiovaskulární kontinuum. Rozhodují komorbidity o volbě terapie? Cor Vasa. 2012;54(5-6):302.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Manolis AJ, Rosei EA, Coca A, et al. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. J Hypertens 2012;30:239-52. Go to original source... Go to PubMed...
    2. Verdecchia P, Reboldi G, Gattobigio R, et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003;41:218-23. Go to original source... Go to PubMed...
    3. Schaer BA, Schneider C, Jick SS, et al. Risk for incident atrial fibrillation in patients who receive antihypertensive drugs: a nested case-control study. Ann Intern Med 2010; 152:78-84. Go to original source... Go to PubMed...
    4. Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-80. Go to original source... Go to PubMed...
    5. De Luca N, Rosiello G, Lamenza F, et al. Reversal of cardiac and large artery structural abnormalities induced by long-term antihypertensive treatment with trandolapril. Am J Cardiol 1992;70:52D-59D. Go to original source... Go to PubMed...
    6. Ruggenenti P, Iliev I, Costa GM, Parvanova A, et al. Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT). Diabetes Care 2008;31:1629-1634. Epub 2008 Apr 28. Go to original source... Go to PubMed...
    7. De Simone A, Stabile G, Vitale DF, et al. Pretreatment with verapamil in patients with persistent or chronic atrial fibrillation who underwent electrical cardioversion. J Am Coll Cardiol 1999;34:810-4. Go to original source... Go to PubMed...
    8. Niwano S, Fukaya H, Sasaki T, et al. Effect of oral L-type calcium channel blocker on repetitive paroxysmal atrial fibrillation: spectral analysis of fibrillation waves in the Holter monitoring. Europace 2007;9:1209-15. Epub 2007 Sep 26. Go to original source... Go to PubMed...
    9. Gayle WR, Lesley JS. Eprosartan. A review of its use in the management of hypertension. Drugs 2005;65:2356. Go to original source...
    10. Edwards RM, Aiyar N, Ohlstein EH, et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992;260: 175-81. Go to PubMed...
    11. Ohlstein EH, Brooks DP, Feuerstein GZ, et al. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997;55:244-51. Go to original source... Go to PubMed...
    12. de la Sierra A, Muñoz A, Arcos E, et al. The effect of treatment with eprosartan on pulse pressure: factors predicting response. Can J Cardiol 2004;20 Suppl C:17C-22C. Go to PubMed...
    13. Schrader J, Lüders S, Kulschewski A, et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005;36:1218-26. Epub 2005 May 5. Go to original source... Go to PubMed...
    14. Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104: 3046-51. Go to original source... Go to PubMed...
    15. Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation 1998;97:1029-36. Go to original source... Go to PubMed...
    16. Miller M, Cannon CP, Murphy SA, et al. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008;51:724-30. Go to original source... Go to PubMed...
    17. Karpe F. Postprandial lipemia - effect of lipid-lowering drugs. Atheroscler Suppl 2002;3:41-6. Go to original source... Go to PubMed...
    18. Grundy SM, Vega GL, Yuan Z, et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). Am J Cardiol 2005;95: 462-8. Go to original source... Go to PubMed...
    19. Nilsson PM. ACCORD and Risk-Factor Control in Type 2 Diabetes. N Engl J Med 2010;362:1628-30. Epub 2010 Mar 14. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes